Equitec Proprietary Markets’s Cidara Therapeutics CDTX Stock Holding History

Equitec Proprietary Markets’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-28,787	Closed	-$6.36M	–	90
2025 Q4	$6.36M	Buy	+28,787	New	+$4.65M	3.65%	6

Equitec Proprietary Markets's CDTX Position: Q1 2026 in Review

Equitec Proprietary Markets sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 28,787 shares — an estimated $6.36M sold.

Equitec Proprietary Markets first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $6.36M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Equitec Proprietary Markets reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Equitec Proprietary Markets sold 28,787 Cidara Therapeutics shares in Q1 2026, an estimated $6.36M.
Equitec Proprietary Markets first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Equitec Proprietary Markets's Cidara Therapeutics position peaked at $6.36M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Equitec Proprietary Markets's 13F filing for Q1 2026, filed 11 May 2026.